Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Costs and expenses:
Research and development	$ 2,637,331	$ 518,040
General and administrative	1,549,606	1,403,660
Total operating expenses	4,186,937	1,921,700
Loss from operations	(4,186,937)	(1,921,700)
Other income (expense):
Change in fair value of debt		(59,641)
Interest on debt		(98,287)
Change in fair value of derivative instruments-warrants and contingent consideration	(39,680)	95,917
Loss before income taxes	(4,226,617)	(1,983,711)
Net loss	(4,226,617)	(1,983,711)
Deemed dividend (see Note 5)		(24,321)
Net loss attributable to common shareholders	$ (4,226,617)	$ (2,008,032)
Weighted average common shares outstanding:
Basic and diluted	4,345,699	250,126
Net loss per common share: (see Note 10)
Basic and diluted	$ (0.97)	$ (8.03)